Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

Ultrasound II: Endoscopic Ultrasound and FibroScan

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):

Acute Pancreatitis II: Clinical Manifestations and Management

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Chronic Pancreatitis I: Introduction

Chronic Pancreatitis I: Introduction

The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Jejunal adenocarcinoma with isolated mesorectal metastasis: a case report of a rare entity.

Journal of surgical case reports·2026

Same author

Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies.

BMC infectious diseases·2024

Same author

Impact of fluvoxamine on outpatient treatment of COVID-19 in Honduras in a prospective observational real-world study.

Frontiers in pharmacology·2022

Same author

A retrospective, multicentre evaluation of eravacycline utilisation in community and academic hospitals.

Journal of global antimicrobial resistance·2021

Same author

Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital.

PloS one·2021

Same author

Wunderlich's Syndrome, or Spontaneous Retroperitoneal Hemorrhage, in a Patient with Tuberous Sclerosis and Bilateral Renal Angiomyolipoma.

The American journal of case reports·2017

Search research articles

Related Experiment Video

Updated: Oct 12, 2025

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

A New Potential Strategy for Acute Non-Alcoholic Steatohepatitis (NASH).

Anupamjeet Kaur Sekhon¹, Aniruddha Gollapalli¹, Dharamjeet Kaur²

¹Texas A&M-affiliated DeTar Family Medicine Residency Program, Victoria, TX, USA.

The American Journal of Case Reports

|November 26, 2021

Summary

PCSK9 inhibitors dramatically improved non-alcoholic steatohepatitis (NASH) and liver histology in a patient with familial hypercholesterolemia. This suggests PCSK9 inhibitors may be a promising therapy for NASH.

More Related Videos

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

Related Experiment Videos

Last Updated: Oct 12, 2025

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

Area of Science:

Hepatology and Metabolic Disorders
Cardiovascular Pharmacology

Background:

Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, with non-alcoholic steatohepatitis (NASH) affecting 25% of patients.
NASH is projected to be the primary indication for liver transplantation by 2030, yet no approved therapies currently exist.
Elevated LDL cholesterol levels are independently linked to an increased risk of NAFLD.

Observation:

A case report details a 39-year-old woman with acute NASH and familial hypercholesterolemia, resistant to lifestyle changes and statins.
Rhabdomyolysis precluded further statin use, necessitating alternative treatments.
Liver biopsy confirmed acute NASH, characterized by microvesicular and macrovesicular steatosis with ballooning degeneration.

Findings:

The patient received PCSK9 inhibitors as salvage therapy, administered monthly.
Within three months, significant improvements were observed: an 80% reduction in ALT and AST levels and a 48% decrease in LDL levels.
An eight-month follow-up liver biopsy revealed normalization of liver histology.

Implications:

PCSK9 inhibitors demonstrated a remarkable therapeutic response in a patient with severe NASH who failed conventional treatments.
These findings highlight the potential of PCSK9 inhibitors as a novel therapeutic strategy for NASH.
Further research is warranted to investigate PCSK9 inhibitors as a potential first-line treatment for the acute phase of NASH.